CA
NZ
UK
AU
IND
US
…
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, sexual wellness products, and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. In addition, it offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. The company operates offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangdong, Guangzhou, Tianjin, and Kunshan. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
111 Inc operates an online healthcare platform in China that retails prescription and over‑the‑counter medicines, health products and related distribution and digital services. Long-term growth drivers include China's aging population, rising adoption of online pharmacies and greater digitalization of healthcare, which may benefit platform volume and logistics scale; the company appears positioned to capture part of the channel shift to e-commerce through its retail and distribution capabilities.
Key investment risks include regulatory changes affecting online drug sales and healthcare policy, intense competition from larger technology and pharmacy players, margin pressure and execution risk in maintaining compliant supply chains and profitability.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -376.07M | -621.02M | -467.11M | -501.83M | -382.03M |
| Minority interest | -40.81M | -48.78M | 973.24M | -2.73M | -0.51M |
| Net income | -408.50M | -662.97M | -459.04M | -492.39M | -380.09M |
| Selling general administrative | 746.54M | 752.10M | 447.24M | 314.40M | 243.94M |
| Selling and marketing expenses | 457.88M | 513.15M | 399.61M | 340.56M | 260.04M |
| Gross profit | 839.98M | 621.10M | 365.83M | 165.18M | 104.27M |
| Reconciled depreciation | 40.82M | 27.22M | - | 11.67M | 11.27M |
| Ebit | -371.00M | -642.14M | -473.31M | -493.51M | -395.76M |
| Ebitda | -354.75M | -617.47M | -463.84M | -487.88M | -384.49M |
| Depreciation and amortization | 16.25M | 24.67M | 9.47M | 5.64M | 11.27M |
| Non operating income net other | - | - | - | 0.00M | 0.00M |
| Operating income | -371.00M | -642.14M | -473.31M | -493.51M | -400.38M |
| Other operating expenses | 13887.70M | 13068.04M | 8676.47M | 4445.57M | 2186.34M |
| Interest expense | 13.44M | 5.49M | 8.82M | 3.62M | 0.00M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.01M |
| Interest income | 8.12M | 9.78M | 6.31M | 4.80M | 4.35M |
| Net interest income | -5.33M | 4.29M | -2.50M | 1.18M | 4.35M |
| Extraordinary items | - | - | - | 0.00M | 0.00M |
| Non recurring | - | - | - | 0.00M | 0.00M |
| Other items | - | - | - | 0.00M | 0.00M |
| Income tax expense | 32.43M | 41.94M | -8.07M | -9.43M | 0.01M |
| Total revenue | 13516.70M | 12425.90M | 8203.16M | 3952.05M | 1785.97M |
| Total operating expenses | 1210.98M | 1263.23M | 839.14M | 658.70M | 504.64M |
| Cost of revenue | 12676.72M | 11804.81M | 7837.32M | 3786.87M | 1681.70M |
| Total other income expense net | -5.07M | 21.11M | 6.20M | -8.31M | 13.99M |
| Discontinued operations | - | - | - | 0.00M | 0.00M |
| Net income from continuing ops | -376.07M | -621.02M | -467.11M | -501.83M | -382.04M |
| Net income applicable to common shares | - | -669.81M | -456.53M | -499.61M | -380.09M |
| Preferred stock and other adjustments | - | - | - | 0.00M | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3089.04M | 3473.81M | 3145.83M | 3026.49M | 1610.29M |
| Intangible assets | 2.26M | 3.27M | 4.91M | 0.92M | 8.02M |
| Other current assets | 9.40M | 282.07M | 5.96M | 4.12M | 6.99M |
| Total liab | 2812.93M | 2825.58M | 2297.13M | 1695.84M | 836.37M |
| Total stockholder equity | -583.45M | -414.60M | -173.32M | 357.40M | 776.66M |
| Deferred long term liab | - | - | - | - | 0.00M |
| Other current liab | 622.27M | 457.70M | 273.50M | 196.10M | 159.24M |
| Common stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.06M |
| Capital stock | 0.06M | 0.06M | 0.06M | 0.06M | 0.06M |
| Retained earnings | -3819.25M | -3426.56M | -3009.68M | -2339.87M | -1883.34M |
| Other liab | - | - | 1.54M | 3.74M | 5.94M |
| Good will | - | - | - | 5.60M | 0.00M |
| Other assets | - | - | 22.09M | 5.06M | 3.01M |
| Cash | 603.52M | 673.67M | 661.39M | 1189.62M | 613.75M |
| Total current liabilities | 2745.06M | 2725.11M | 2129.98M | 1629.72M | 745.63M |
| Current deferred revenue | 153.50M | 323.57M | 202.56M | 131.01M | 74.77M |
| Net debt | -160.29M | -394.21M | -236.12M | -897.98M | -461.65M |
| Short term debt | 380.61M | 178.99M | 259.66M | 229.25M | 95.08M |
| Short long term debt | 338.07M | 178.99M | 259.66M | 229.25M | 95.08M |
| Short long term debt total | 443.23M | 279.46M | 425.27M | 291.64M | 152.09M |
| Other stockholder equity | 3163.23M | 2936.32M | 2776.93M | 2634.31M | 2583.49M |
| Property plant equipment | - | - | 314.10M | 142.07M | 117.69M |
| Total current assets | 2933.33M | 3235.82M | 2801.74M | 2872.70M | 1481.43M |
| Long term investments | 2.00M | 2.00M | 3.00M | 0.14M | 0.14M |
| Net tangible assets | - | - | -178.23M | 350.89M | 768.63M |
| Short term investments | 50.14M | 205.86M | 182.56M | 300.17M | 0.00M |
| Net receivables | 776.51M | 532.21M | 495.20M | 175.68M | 88.83M |
| Long term debt | - | - | - | - | 0.00M |
| Inventory | 1419.40M | 1498.90M | 1121.11M | 766.53M | 486.27M |
| Accounts payable | 1588.69M | 1764.85M | 1394.25M | 1073.35M | 416.54M |
| Total permanent equity | - | - | - | - | 0.00M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00M |
| Accumulated other comprehensive income | 72.51M | 75.59M | 59.37M | 62.91M | 76.44M |
| Additional paid in capital | - | - | - | - | 0.00M |
| Common stock total equity | - | - | - | 0.06M | 0.06M |
| Preferred stock total equity | - | - | - | - | 0.00M |
| Retained earnings total equity | - | - | - | - | 0.00M |
| Treasury stock | - | - | - | - | -22.99M |
| Accumulated amortization | - | - | - | - | 0.00M |
| Non currrent assets other | 13.31M | 20.35M | 22.09M | 5.06M | 3.01M |
| Deferred long term asset charges | - | - | - | - | 0.00M |
| Non current assets total | 155.71M | 237.99M | 344.10M | 153.78M | 128.86M |
| Capital lease obligations | 105.15M | 100.47M | 165.61M | 62.39M | 88.11M |
| Long term debt total | - | - | - | - | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -47.17M | 60.14M | -324.67M | 262.11M | 44.45M |
| Change to liabilities | - | 274.00M | 629.02M | 232.08M | 84.12M |
| Total cashflows from investing activities | - | 60.14M | -324.67M | 237.68M | 44.45M |
| Net borrowings | - | 30.41M | 134.17M | 95.08M | 95.08M |
| Total cash from financing activities | 22.73M | 27.44M | 1070.41M | 106.95M | 972.70M |
| Change to operating activities | - | -0.92M | -22.17M | -23.22M | -23.01M |
| Net income | -376.07M | -621.02M | -456.53M | -501.83M | -382.04M |
| Change in cash | -43.88M | -557.86M | 620.81M | -156.02M | 686.08M |
| Begin period cash flow | 760.67M | 1318.53M | 697.72M | 853.74M | 167.66M |
| End period cash flow | 716.79M | 760.67M | 1318.53M | 697.72M | 853.74M |
| Total cash from operating activities | -23.15M | -641.94M | -116.78M | -510.19M | -343.02M |
| Issuance of capital stock | 0.27M | 2.92M | 6.33M | 11.33M | 972.70M |
| Depreciation | 40.82M | 27.22M | 14.02M | 11.67M | 11.27M |
| Other cashflows from investing activities | - | 60.14M | -324.67M | -324.67M | -324.67M |
| Dividends paid | - | -359.94M | - | -148.88M | 0.00M |
| Change to inventory | 28.50M | -400.55M | 24.22M | -276.23M | -66.78M |
| Change to account receivables | -86.98M | -242.40M | -98.28M | -36.68M | -8.17M |
| Sale purchase of stock | 0.00M | -5.89M | -11.98M | -22.99M | 972.70M |
| Other cashflows from financing activities | 891.28M | 766.77M | 1076.06M | 323.32M | 277.82M |
| Change to netincome | - | 27.87M | 339.76M | 79.60M | 39.65M |
| Capital expenditures | 31.57M | 62.69M | 25.50M | 24.61M | 14.82M |
| Change receivables | - | - | - | 0.00M | 0.00M |
| Cash flows other operating | - | - | - | 0.00M | 0.00M |
| Exchange rate changes | - | - | - | 0.00M | 0.00M |
| Cash and cash equivalents changes | - | - | - | 0.00M | 0.00M |
| Change in working capital | 359.02M | -369.87M | 4.97M | -103.26M | -13.84M |
| Stock based compensation | 162.07M | 145.59M | 75.69M | 54.28M | 51.36M |
| Other non cash items | -208.99M | 89.78M | 334.79M | 25.39M | -11.71M |
| Free cash flow | -54.73M | -704.63M | -142.28M | -534.80M | -357.84M |
Sector: Healthcare Industry: Medical Distribution
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| YI 111 Inc |
0.02 0.72% |
2.95 | - | - | 0.01 | -0.69 | 0.00 | -0.13 |
| MCK McKesson Corporation |
4.53 0.43% |
1063.90 | 24.45 | 20.41 | 0.26 | 5.04 | 0.27 | 15.03 |
| COR Cencora Inc. |
-2.51 0.73% |
343.25 | 24.22 | 16.39 | 0.19 | 20.41 | 0.21 | 13.72 |
| CAH Cardinal Health Inc |
-0.93 0.34% |
273.36 | 29.48 | 17.92 | 0.20 | 16.07 | 0.22 | 15.67 |
| HSIC Henry Schein Inc |
0.05 0.06% |
88.46 | 25.89 | 15.08 | 0.72 | 3.14 | 1.00 | 13.43 |
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, sexual wellness products, and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. In addition, it offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. The company operates offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangdong, Guangzhou, Tianjin, and Kunshan. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Gang Yu | Co-Founder & Exec. Chairman | 1959 |
| Mr. Junling Liu | Co-Founder, Acting CFO, Chairman & CEO | 1965 |
| Mr. Haihui Wang | Co-Chief Operating Officer | NA |
| Mr. Pengcheng Zhu | Co-Chief Operating Officer | NA |
| Monica Mu | IR Director | NA |
| Mr. Anfeng Guo | Chief Innovation Officer | NA |
| Mr. Yang Chen | CFO at Yaofang Information Technology (Shanghai) Co., Ltd. | 1971 |
| Mr. Alex Liu | Fin. Director | NA |
| Dr. Gang Yu | Co-Founder & Executive Chairman | 1959 |
| Mr. Alex Liu | Finance Director | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.10%
Communication Services
-0.42%
Consumer Cyclical
-0.41%
Consumer Defensive
-0.22%
Energy
-0.09%
Financial Services
-0.14%
Financials
-0.48%
Healthcare
-0.20%
Industrials
-0.11%
Real Estate
-0.53%
Technology
-0.23%
Utilities
-0.53%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+1.15%
Please wait processing your request...